Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Pfizer halted its oral obesity drug, danuglipron, in April 2025 due to liver injury concerns, a major pipeline setback. Find ...

Pharmaceutical rivals don’t often come to each other’s defense. But after the US Department of Health and Human Services ...

Pfizer ( PFE 1.46%) made a fortune thanks to its work in the COVID-19 market. In 2022, it became the first company in the ...

Pfizer jumps into cancer-treatment race with a $6 billion licensing deal with a China-based company, six months after Merck’s ...

Pfizer announced last month that it was discontinuing development of its experimental weight-loss pill, danuglipron, after a trial participant experienced potential drug-induced liver injury.

Last week, Pfizer announced that it would no longer develop danuglipron, a daily GLP-1 weight-loss drug which investors ... 20.5 billion in cash and short-term investments. With strong financials ...

With a strong dividend yield of 7.48% and a history of maintaining dividend payments for 55 consecutive years, Pfizer demonstrates robust financial stability for such significant investments.

He added that Pfizer is being "very frugal" with investments so it can be "prepared ... billionaire investor Mark Cuban said in March that drugs from his company, Cost Plus Drugs, will likely ...

Pharmaceutical stocks, including Pfizer (NYSE: PFE), have recently been scrutinized after President Trump’s executive order instructing drug manufacturers to reduce medicine prices to align with ...

The drug giant continues to face an "uncertain and volatile external environment," he said. Pfizer's stock rose ... of products and services to both investment professionals and individual investors.